Sciencast Management LP Has $1.61 Million Holdings in Johnson & Johnson (NYSE:JNJ)
Sciencast Management LP lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,170 shares of the company’s stock after buying an additional 670 shares during the period. Sciencast Management LP’s holdings in Johnson & Johnson were worth $1,612,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $25,000. Krane Funds Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $26,000. Financial Advantage Inc. acquired a new stake in Johnson & Johnson in the third quarter valued at $28,000. Crewe Advisors LLC increased its holdings in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the period. Finally, Eii Capital Management Inc. acquired a new stake in Johnson & Johnson in the third quarter valued at $39,000. Institutional investors own 72.25% of the company’s stock.
A number of research firms recently weighed in on JNJ. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a report on Thursday, October 17th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Friday, October 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Morgan Stanley restated an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Tuesday, August 27th. Finally, Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $151.64.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.05 EPS. On average, analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Float
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.